Moreover, serum β2-m levels have been associated with the malignancy of lymphoma [18] and elevated in 40–55% of patients with aggressive non-Hodgkin's lymphoma [19, 20], with the proportion of patients having elevated serum β2-m varying by the primary site of diseases [21]. Here, B2M is linked to non-Hodgkin lymphoma.